Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This early phase I trial studies how well levorphanol works as a second line opioid in
reducing pain in patients with cancer that may have spread to other places in the body.
Levorphanol may work better in controlling cancer pain.